Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of 497.77 billion. The enterprise value is 496.95 billion.
| Market Cap | 497.77B |
| Enterprise Value | 496.95B |
Important Dates
The next estimated earnings date is Wednesday, November 6, 2024.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | Aug 15, 2024 |
Share Statistics
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.90% |
| Shares Change (QoQ) | -0.11% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.17B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 26.69, with an EV/FCF ratio of 42.62.
| EV / Earnings | 38.48 |
| EV / Sales | 13.23 |
| EV / EBITDA | 26.69 |
| EV / EBIT | 28.77 |
| EV / FCF | 42.62 |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.51.
| Current Ratio | 0.94 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | 0.45 |
| Debt / FCF | 0.70 |
| Interest Coverage | 218.77 |
Financial Efficiency
Return on equity (ROE) is 88.57% and return on invested capital (ROIC) is 51.87%.
| Return on Equity (ROE) | 88.57% |
| Return on Assets (ROA) | 22.80% |
| Return on Capital (ROIC) | 51.87% |
| Revenue Per Employee | 535,204 |
| Profits Per Employee | 186,485 |
| Employee Count | 64,319 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 1.24 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +21.84% in the last 52 weeks. The beta is 0.15, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | +21.84% |
| 50-Day Moving Average | 125.02 |
| 200-Day Moving Average | 128.09 |
| Relative Strength Index (RSI) | 36.77 |
| Average Volume (20 Days) | 37,420 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novo Nordisk had revenue of 37.07 billion and earned 12.92 billion in profits. Earnings per share was 2.89.
| Revenue | 37.07B |
| Gross Profit | 31.33B |
| Operating Income | 17.04B |
| Pretax Income | 16.23B |
| Net Income | 12.92B |
| EBITDA | 18.18B |
| EBIT | 17.04B |
| Earnings Per Share (EPS) | 2.89 |
Balance Sheet
The company has 9.00 billion in cash and 8.20 billion in debt, giving a net cash position of 803.71 million.
| Cash & Cash Equivalents | 9.00B |
| Total Debt | 8.20B |
| Net Cash | 803.71M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 16.17B |
| Book Value Per Share | 3.63 |
| Working Capital | -1.50B |
Cash Flow
In the last 12 months, operating cash flow was 16.57 billion and capital expenditures -4.91 billion, giving a free cash flow of 11.66 billion.
| Operating Cash Flow | 16.57B |
| Capital Expenditures | -4.91B |
| Free Cash Flow | 11.66B |
| FCF Per Share | n/a |
Margins
Gross margin is 84.53%, with operating and profit margins of 45.96% and 34.84%.
| Gross Margin | 84.53% |
| Operating Margin | 45.96% |
| Pretax Margin | 43.77% |
| Profit Margin | 34.84% |
| EBITDA Margin | 49.05% |
| EBIT Margin | 45.96% |
| FCF Margin | 31.46% |
Dividends & Yields
This stock pays an annual dividend of 0.52, which amounts to a dividend yield of 0.46%.
| Dividend Per Share | 0.52 |
| Dividend Yield | 0.46% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 46.71% |
| Buyback Yield | 0.90% |
| Shareholder Yield | 1.36% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
The last stock split was on September 13, 2023. It was a forward split with a ratio of 2.
| Last Split Date | Sep 13, 2023 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Novo Nordisk has an Altman Z-Score of 9.98.
| Altman Z-Score | 9.98 |
| Piotroski F-Score | n/a |